Aperio Group LLC increased its position in shares of Danaher Corporation (NYSE:DHR) by 6.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 508,789 shares of the company’s stock after purchasing an additional 32,860 shares during the period. Aperio Group LLC owned 0.07% of Danaher Corporation worth $43,644,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the stock. ETRADE Capital Management LLC boosted its stake in Danaher Corporation by 5.1% in the second quarter. ETRADE Capital Management LLC now owns 19,075 shares of the company’s stock valued at $1,610,000 after acquiring an additional 917 shares in the last quarter. Honeywell International Inc. acquired a new position in Danaher Corporation in the second quarter valued at $25,317,000. Roundview Capital LLC boosted its stake in Danaher Corporation by 2.0% in the second quarter. Roundview Capital LLC now owns 25,674 shares of the company’s stock valued at $2,167,000 after acquiring an additional 502 shares in the last quarter. Israel Discount Bank of New York acquired a new position in Danaher Corporation in the first quarter valued at $209,000. Finally, Eastern Bank boosted its stake in Danaher Corporation by 4,291.1% in the second quarter. Eastern Bank now owns 128,001 shares of the company’s stock valued at $10,802,000 after acquiring an additional 125,086 shares in the last quarter. Hedge funds and other institutional investors own 75.38% of the company’s stock.
Shares of Danaher Corporation (NYSE DHR) opened at C$92.24 on Monday. Danaher Corporation has a 1 year low of C$76.27 and a 1 year high of C$93.36. The stock has a market cap of $64,162.62, a P/E ratio of 23.71, a P/E/G ratio of 2.19 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43.
Danaher Corporation (NYSE:DHR) last announced its quarterly earnings results on Thursday, October 19th. The company reported C$1.00 earnings per share for the quarter, beating the Zacks’ consensus estimate of C$0.95 by C$0.05. The company had revenue of C$4.53 billion for the quarter, compared to analyst estimates of C$4.47 billion. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. Danaher Corporation’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the business earned $0.87 EPS. analysts forecast that Danaher Corporation will post 3.99 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, October 27th. Shareholders of record on Friday, September 29th were issued a $0.14 dividend. The ex-dividend date was Thursday, September 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.61%. Danaher Corporation’s dividend payout ratio (DPR) is presently 16.52%.
Several research firms have issued reports on DHR. Robert W. Baird upped their price objective on shares of Danaher Corporation from $87.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. Credit Suisse Group upped their target price on shares of Danaher Corporation from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Morgan Stanley upped their target price on shares of Danaher Corporation from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 20th. Zacks Investment Research raised shares of Danaher Corporation from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a report on Thursday, October 5th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $90.00 target price on shares of Danaher Corporation in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Danaher Corporation currently has a consensus rating of “Buy” and a consensus target price of C$93.31.
In other news, insider William King sold 43,688 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of C$82.86, for a total value of C$3,619,987.68. Following the transaction, the insider now owns 45,748 shares of the company’s stock, valued at approximately C$3,790,679.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of C$92.64, for a total transaction of C$11,671,620.96. Following the completion of the transaction, the chief executive officer now directly owns 271,737 shares in the company, valued at approximately C$25,173,715.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 279,628 shares of company stock worth $25,304,394. 12.20% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Aperio Group LLC Has $43.64 Million Position in Danaher Corporation (DHR)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/11/13/aperio-group-llc-has-43-64-million-position-in-danaher-corporation-dhr.html.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.